Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of BAY 43-9006 (Sorafenib) in Metastatic Renal Cell Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00126659
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:05.421265+00:00
Published At
2012-12-31T00:00:00+00:00
Record Updated At
2018-11-20
Results Posted At
2012-12-31
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Clear Cell Renal Cell Carcinoma", "Recurrent Renal Cell Cancer", "Stage IV Renal Cell Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-11-20"
protocolSection.identificationModule.nctId
"NCT00126659"
protocolSection.identificationModule.officialTitle
"A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of BAY 43-9006 (Sorafenib) in Metastatic Renal Cell Carcinoma"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2012-12-31"

Study condition terms

  • Clear Cell Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Renal Cell Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Renal Cell Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.